Orchid Pharma receives DCGI approval for combination of Cefepime and Enmetazobactam
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
This facility manufactures APIs & formulations of oncology and non-oncology products.
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
A five-day inspection was concluded successfully with no critical and no major observations raised
Additional capacity broadens Grace’s fine chemical capabilities for API production
The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes
Subscribe To Our Newsletter & Stay Updated